Plasma Exchange Arrives in the UK as Circulate Health Teams Up With London Clinic
Circulate Health brings its therapeutic plasma exchange protocol to the UK via a partnership with London's Reborne longevity clinic.
Summary
Therapeutic plasma exchange — a procedure that filters and replaces blood plasma — is now available in the UK through a new partnership between US biotech Circulate Health and London's Reborne clinic. Circulate Health, founded on research from the Buck Institute for Research on Aging and backed by Khosla Ventures, raised $12 million in 2025 and has published peer-reviewed research including a randomised controlled trial suggesting TPE can measurably reduce biological age. Reborne, a CQC-licensed private concierge longevity clinic in Marylebone, becomes the first European partner for Circulate's standardised TPE protocols. The procedure uses FDA-cleared apheresis technology under clinical supervision, separating plasma from whole blood before replacing it with a substitute fluid. This marks a significant step in bringing a clinically supervised, research-backed longevity intervention to European patients.
Detailed Summary
Therapeutic plasma exchange has long been used in medicine to treat autoimmune diseases, but a growing body of longevity research suggests it may also slow or partially reverse biological aging. Circulate Health, a US biotech rooted in Buck Institute research, has now brought this intervention to the UK through an exclusive partnership with Reborne, London's first private concierge longevity clinic.
The procedure works by separating blood plasma from whole blood using FDA-cleared apheresis technology. The plasma — which accumulates pro-aging proteins over time — is removed and replaced with a substitute fluid. Circulate Health deploys standardised TPE protocols across a US clinic network and claims its approach is grounded in peer-reviewed science, including a single-blind, randomised, placebo-controlled human trial that reported measurable reductions in biological age markers.
Circulate Health secured a $12 million seed round in 2025 and counts Khosla Ventures among its backers — a strong signal of investor confidence in the therapeutic plasma exchange space. Reborne, a CQC-licensed independent hospital based in Marylebone, becomes Circulate's first European partner, positioning the UK at the forefront of clinically supervised longevity interventions.
For health-conscious adults, the practical implication is meaningful: access to a research-backed, physician-supervised biological age intervention is now available in the UK without travelling to the US. This lowers the barrier significantly for those already engaged in longevity optimisation strategies such as biomarker tracking, hormonal optimisation, or advanced supplementation protocols.
Important caveats remain. The supporting trial is described as single-blind, which is a methodological limitation compared to double-blind gold standards. Long-term outcomes, optimal dosing frequency, and who benefits most from TPE are still being established. Cost and access will also limit uptake to a narrow, affluent demographic for now. Independent verification of biological age outcomes from multiple trials will be essential before TPE becomes a mainstream longevity tool.
Key Findings
- Circulate Health's TPE protocol is now available in the UK for the first time via London's Reborne clinic.
- A randomised controlled trial reported measurable biological age reductions following therapeutic plasma exchange.
- Circulate Health raised $12 million in 2025 and is backed by Khosla Ventures, signalling strong commercial momentum.
- The procedure uses FDA-cleared apheresis technology under clinical supervision to replace pro-aging plasma proteins.
- Reborne is CQC-licensed, offering a regulated clinical environment for this emerging longevity intervention.
Methodology
This is a news report based on a corporate partnership announcement rather than a primary research publication. The source, Longevity.Technology, is a specialist longevity media outlet with reasonable credibility in the sector. Evidence cited includes a peer-reviewed single-blind RCT, but details of that trial are not provided in the article and require independent verification.
Study Limitations
The article is a partnership announcement and does not detail trial methodology, sample sizes, or specific biological age markers measured in Circulate Health's published research. The single-blind trial design is a limitation worth noting, and long-term safety and efficacy data remain limited. Cost, eligibility criteria, and treatment frequency are not disclosed and should be confirmed directly with Reborne or Circulate Health.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: